In Vitro Digestion of Starches in a Dynamic Gastrointestinal Model: an Innovative Study to Optimize Dietary Management of Patients with Hepatic Glycogen Storage Diseases

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2014 Sep 17

PMID 25224825

Citations 9

Authors

Tatiele Nalin

Koen Venema

David A Weinstein

Carolina F M de Souza

Ingrid D S Perry

Mario T R van Wandelen

Margreet van Rijn

G Peter A Smit

Ida V D Schwartz

Terry G J Derks

Affiliations

Soon will be listed here.

Abstract

Uncooked cornstarch (UCCS) is a widely used treatment strategy for patients with hepatic glycogen storage disease (GSD). It has been observed that GSD-patients display different metabolic responses to different cornstarches. The objective was to characterize starch fractions and analyze the digestion of different starches in a dynamic gastrointestinal in vitro model. The following brands of UCCS were studied: Argo and Great Value from the United States of America; Brazilian Maizena Duryea and Yoki from Brazil; Dutch Maizena Duryea from the Netherlands. Glycosade, a modified starch, and sweet polvilho, a Brazilian starch extracted from cassava, were also studied. The starch fractions were analyzed by glycemic TNO index method and digestion analyses were determined by the TIM-1 system, a dynamic, computer-controlled, in vitro gastrointestinal model, which simulates the stomach and small intestine. The final digested amounts were between 84 and 86% for the UCCS and Glycosade, but was 75.5% for sweet povilho. At 180 min of the experiment, an important time-point for GSD patients, the digested amount of the starches corresponded to 67.9-71.5 for the UCCS and Glycosade, while it was 55.5% for sweet povilho. In an experiment with a mixture of sweet polvilho and Brazilian Maizena Duryea, a final digested amount of 78.4% was found, while the value at 180 min was 61.7%. Sweet polvilho seems to have a slower and extended release of glucose and looks like an interesting product to be further studied as it might lead to extended normoglycemia in GSD-patients.

Citing Articles

Potential use of other starch sources in the treatment of glycogen storage disease type Ia - an in vitro study.

Monteiro V, Colonetti K, Pagno C, Schmidt H, Sperb-Ludwig F, de Oliveira B Orphanet J Rare Dis. 2024; 19(1):283.

PMID: 39080776 PMC: 11289971. DOI: 10.1186/s13023-024-03201-1.

Are the Bacteria and Their Metabolites Contributing for Gut Inflammation on GSD-Ia Patients?.

Colonetti K, de Carvalho E, Rangel D, Pinto P, Roesch L, Pinheiro F Metabolites. 2022; 12(9).

PMID: 36144277 PMC: 9504798. DOI: 10.3390/metabo12090873.

Development of minimally invasive C-glucose breath test to examine different exogenous carbohydrate sources in patients with glycogen storage disease type Ia.

Turki A, Stockler S, Sirrs S, Salvarinova R, Ho G, Branov J Mol Genet Metab Rep. 2022; 31:100880.

PMID: 35585965 PMC: 9109185. DOI: 10.1016/j.ymgmr.2022.100880.

Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs.

Derks T, Rodriguez-Buritica D, Ahmad A, de Boer F, Couce M, Grunert S Nutrients. 2021; 13(11).

PMID: 34836082 PMC: 8621617. DOI: 10.3390/nu13113828.

A triple-blinded crossover study to evaluate the short-term safety of sweet manioc starch for the treatment of glycogen storage disease type Ia.

Monteiro V, de Oliveira B, Dos Santos B, Sperb-Ludwig F, Refosco L, Nalin T Orphanet J Rare Dis. 2021; 16(1):254.

PMID: 34082801 PMC: 8173866. DOI: 10.1186/s13023-021-01877-3.

References

Hatanaka M, Nakamura Y, Maathuis A, Venema K, Murota I, Yamamoto N . Influence of Bacillus subtilis C-3102 on microbiota in a dynamic in vitro model of the gastrointestinal tract simulating human conditions. Benef Microbes. 2012; 3(3):229-36. DOI: 10.3920/BM2012.0016. View

Eelderink C, Moerdijk-Poortvliet T, Wang H, Schepers M, Preston T, Boer T . The glycemic response does not reflect the in vivo starch digestibility of fiber-rich wheat products in healthy men. J Nutr. 2012; 142(2):258-63. DOI: 10.3945/jn.111.147884. View

Correia C, Bhattacharya K, Lee P, Shuster J, Theriaque D, Shankar M . Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. Am J Clin Nutr. 2008; 88(5):1272-6. PMC: 3808112. DOI: 10.3945/ajcn.2008.26352. View

Chen Y, Cornblath M, Sidbury J . Cornstarch therapy in type I glycogen-storage disease. N Engl J Med. 1984; 310(3):171-5. DOI: 10.1056/NEJM198401193100306. View

Di Rocco M, Calevo M, Taro M, Melis D, Allegri A, Parenti G . Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease. Mol Genet Metab. 2007; 93(4):398-402. DOI: 10.1016/j.ymgme.2007.10.134. View

Lee P, Dixon M, Leonard J . Uncooked cornstarch--efficacy in type I glycogenosis. Arch Dis Child. 1996; 74(6):546-7. PMC: 1511553. DOI: 10.1136/adc.74.6.546. View

Moses S . Historical highlights and unsolved problems in glycogen storage disease type 1. Eur J Pediatr. 2002; 161 Suppl 1:S2-9. DOI: 10.1007/s00431-002-0997-6. View

Burr I, ONeill J, Karzon D, Howard L, Greene H . Comparison of the effects of total parenteral nutrition, continuous intragastric feeding, and portacaval shunt on a patient with type I glycogen storage disease. J Pediatr. 1974; 85(6):792-5. DOI: 10.1016/s0022-3476(74)80342-2. View

Bhattacharya K, Orton R, Qi X, Mundy H, Morley D, Champion M . A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis. 2007; 30(3):350-7. DOI: 10.1007/s10545-007-0479-0. View

10.

Derks T, Martens D, Sentner C, van Rijn M, de Boer F, Smit G . Dietary treatment of glycogen storage disease type Ia: uncooked cornstarch and/or continuous nocturnal gastric drip-feeding?. Mol Genet Metab. 2013; 109(1):1-2. DOI: 10.1016/j.ymgme.2013.02.005. View

11.

Greene H, Slonim A, ONEILL Jr J, Burr I . Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease. N Engl J Med. 1976; 294(8):423-5. DOI: 10.1056/NEJM197602192940805. View

12.

Eelderink C, Schepers M, Preston T, Vonk R, Oudhuis L, Priebe M . Slowly and rapidly digestible starchy foods can elicit a similar glycemic response because of differential tissue glucose uptake in healthy men. Am J Clin Nutr. 2012; 96(5):1017-24. DOI: 10.3945/ajcn.112.041947. View

13.

van Amelsvoort J, Weststrate J . Amylose-amylopectin ratio in a meal affects postprandial variables in male volunteers. Am J Clin Nutr. 1992; 55(3):712-8. DOI: 10.1093/ajcn/55.3.712. View

14.

Weinstein D, Wolfsdorf J . Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr. 2002; 161 Suppl 1:S35-9. DOI: 10.1007/s00431-002-1000-2. View

15.

Lafond M, Bouza B, Eyrichine S, Bonnin E, Crost E, Geraert P . An integrative in vitro approach to analyse digestion of wheat polysaccharides and the effect of enzyme supplementation. Br J Nutr. 2011; 106(2):264-73. DOI: 10.1017/S0007114511000134. View

16.

Minekus M, Smeets-Peeters M, Bernalier A, Marol-Bonnin S, Havenaar R, Marteau P . A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products. Appl Microbiol Biotechnol. 2000; 53(1):108-14. DOI: 10.1007/s002530051622. View

17.

Anderson G, Cho C, Akhavan T, Mollard R, Luhovyy B, Finocchiaro E . Relation between estimates of cornstarch digestibility by the Englyst in vitro method and glycemic response, subjective appetite, and short-term food intake in young men. Am J Clin Nutr. 2010; 91(4):932-9. DOI: 10.3945/ajcn.2009.28443. View

18.

Rake J, Visser G, Labrune P, Leonard J, Ullrich K, Smit G . Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002; 161 Suppl 1:S20-34. DOI: 10.1007/s00431-002-0999-4. View

19.

Weinstein D, Somers M, Wolfsdorf J . Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr. 2001; 138(3):378-82. DOI: 10.1067/mpd.2001.111322. View

20.

Englyst K, Englyst H, Hudson G, Cole T, Cummings J . Rapidly available glucose in foods: an in vitro measurement that reflects the glycemic response. Am J Clin Nutr. 1999; 69(3):448-54. DOI: 10.1093/ajcn/69.3.448. View